MEDARTIS: Aiming for market leadership!

The recently released financial results from the medtech company MEDARTIS were impressive and even slightly exceeded market expectations. We therefore followed the Investor Day on June 4 with keen interest, hoping to identify any potential weaknesses in the company’s strategy. But the opposite was true: Management presented a clear vision and underscored its ambitious growth targets. With its “From Head to Toe” strategic approach, MEDARTIS aims to further expand its position in attractive niche markets. Particularly in the field of hand and wrist implants, the company has a first-class product portfolio and is aiming for global market leadership. A particular highlight is the innovative TOUCH thumb prosthesis, which was added to the portfolio through the acquisition of KeriMedical. The prosthesis is the only product of its kind to date to have received approval from the U.S. Food and Drug Administration (FDA) and is generating significant interest in the market. 150 procedures are performed each month. This, too, impressively confirms the aforementioned first-class quality in medical technology!

Management is extremely confident about the coming years. In the U.S., growth is set to accelerate further, and additional market potential will be tapped. This market is expected to continue growing at over 20% per year! Other strategic priorities include expansion in Latin America and the continuous improvement of cash flow. The forecast for the current fiscal year has been confirmed and anticipates revenue growth of +16% to +18% as well as a core EBITDA margin in the high 10% range. The Investor Day has further reinforced our positive impression! MEDARTIS has attractive growth drivers, innovative products, and a compelling market position. The current weakness in the share price can be used to further build out our position. Price target: CHF 110!